Invention:
This invention is a new formulation for the treatment of Alzheimer’s Disease. Through the application of a novel computational systems biology approach, the inventors have identified several therapeutic targets of single cell type and whole bulk tissue that contribute to Alzheimer’s Disease, which can be used individually or in combination with other drugs. Validation studies with human primary neurons and primary microglials have been conducted. The discovery of these new therapeutic targets has the potential to be highly innovative and can lead to clinical trials, small business development in nutraceutical and pharmaceutical licensing opportunities.
Background:
Alzheimer’s disease (AD) is a chronic neurodegenerative disease that progresses over time. It is the cause of 60% to 70% of cases of dementia, and over 36 million people worldwide. The active study of Alzheimer’s drug by pharmaceutical industries and research institutes for creating a strong pipeline for effective therapy is predicted to encourage growth of the global Alzheimer’s drugs market. According to the World Health Organization (WHO) currently, 50 million people are affected by dementia, and the number is expected to increase. In addition, the increasing cases of Alzheimer’s disease around the world have led towards high demand for Alzheimer’s drugs, which in turn is boosting the global Alzheimer’s drugs growth. However, discontinuation of clinical trials for Alzheimer’s drugs by leading pharmaceutical companies is resulting in limited treatment options and thus creating a global economic burden by increasing the nation’s annual treatment cost against Alzheimer’s drugs development and disease treatment.
Applications:
- Novel therapeutics for Alzheimer’s disease
Advantages:
- Highly innovative
- Can play a role in a rapidly increasing market
- Treats a condition that continues to affect humans in ever-increasing numbers
